Comparative Pharmacology
Head-to-head clinical analysis: AREDIA versus BONCRESA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AREDIA versus BONCRESA.
AREDIA vs BONCRESA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.
BONCRESA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and readily excreted metabolite, thereby reducing serum uric acid levels.
90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.
5 mg orally once daily, with or without food; maximum dose 10 mg once daily.
None Documented
None Documented
Multiphasic; terminal half-life is approximately 300 hours (range 200-400 hours) reflecting slow release from bone. Clinically, this results in prolonged suppression of bone resorption lasting weeks after a single dose.
Terminal elimination half-life: 12 hours (range 10-14 h); clinically relevant for once-daily dosing
Primarily eliminated unchanged via renal excretion (about 30-40% of administered dose within 24 hours); remainder sequestered in bone and slowly released over months. Biliary/fecal excretion is negligible (<1%).
Renal: 70% unchanged; fecal: 20% as metabolites; biliary: minor (<5%)
Category C
Category C
Bisphosphonate
Bisphosphonate